BioSyent Signs Exclusive Agreement for Oncology Supportive Care Product
December 14 2022 - 3:50PM
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is
pleased to announce that its subsidiary, BioSyent Pharma Inc., has
signed an exclusive Distribution Agreement with a European partner
for a product that is used in oncology supportive care. The product
has been marketed in Europe, USA and several other markets around
the world to help cancer patients with certain side effects of
their treatment. BioSyent anticipates launching the product in
Canada in late 2023, pending regulatory approval.
“We are pleased to add this new product to our
growing portfolio which provides us with an opportunity to not only
grow our top line revenue but also to enter a new therapeutic area
of oncology supportive care,” said René Goehrum, President and CEO
of BioSyent. “This oncology supportive care product aligns with our
strategic objectives of growth, portfolio diversification, and
corporate longevity by bringing products to Canada that are unique,
differentiated and treat unmet medical needs.”
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community, specialty
and international business units.
As of the date of this press release, the
Company has 12,097,861 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
This press release may contain information or
statements that are forward-looking. The contents herein represent
our judgment, as at the release date, and are subject to risks and
uncertainties that may cause actual results or outcomes to be
materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to,
those associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Aug 2023 to Aug 2024